The Society for Brain Mapping and Therapeutics (SMBT) 12th Annual World Congress Black Tie Gala was held on Saturday, March 7, 2015 at the Los Angeles Millennium Biltmore Hotel, Los Angeles, CA, during which the Society awarded the “Beacon of Courage and Dedication Award” to Professor Stephen Hawking — a living ALS medical miracle. Recorded on…
Search results for:
The Augie’s Quest initiative is hosting a 10 Year Reunion Bash on Friday, March 13. The event, which is being organized together with the 34th Annual IHRSA Tradeshow and Convention is taking place at the JW Marriott, in Los Angeles, California and the funds raised are going to be used to support the ALS Therapy Development…
‘My-own-voice,’ a system for patients who are losing their ability to speak due to diseases such as amyotrophic lateral sclerosis (ALS) to record and later use their voice to communicate, was presented at the Annual International Technology and Persons with Disabilities Conference (CSUN). The Acapela…
On February 23rd, the office of the Congressionally Directed Medical Research Programs (CDMRP) released a pre-announcement through the Department of Defense Amyotrophic Lateral Sclerosis Research Program (ALSRP) for the opening of the FY15 appropriations grant application cycle. This pre-announcement is meant to give investigators the opportunity to begin preparations for submitting…
Biopharmaceutical company MediciNova, Inc. recently completed enrollment of the first 30 patients with amyotrophic lateral sclerosis (ALS) for its clinical trial to evaluate the efficacy MN-166 (ibudilast). The company plans to add another 30 participants…
The first app for amyotrophic lateral sclerosis (ALS) patients who have begun to lose their speaking abilities was recently launched by UK company Therapy Box. The app was designed to substitute standard text-to-speech synthesis with a synthesizer based on the patient’s own voice. The Predictable 4 app has entered the ModelTalker program, at a…
Dr. Nancy Bonini A recent editorial published in the journal Neurology highlights the existing scope of clinical knowledge concerning genetic susceptibility that makes individuals prone to developing amyotrophic lateral sclerosis (ALS). The editorial content was based on a thorough…
Newron Pharmaceuticals is about to initiate its Phase II clinical trial, designed to evaluate novel molecule sNN0029 in patients who suffer from Amyotrophic Lateral Sclerosis (ALS), according to information provided by the company in a press release. The company, which has been dedicated to providing CNS…
Treeway, a biotechnological company based in the Netherlands, founded by Bernard Muller and Robbert Jan Stuit, who are both entrepreneurs and both diagnosed with amyotrophic lateral sclerosis (ALS), recently announced a collaboration with uniQure, a Dutch company specialized in gene therapy to develop a treatment for the disease.
AB Science SA, a pharmaceutical company focused on research, advancement and commercialization of protein kinase inhibitors (PKIs) announced that the external Data and Safety Monitoring Board (DSMB) recommended the company’s phase 3 study of masitinib in amyotrophic lateral sclerosis (ALS) be continued. The decision was supported by the drug’s latest safety reports. The current…